2‑Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells

Oncology Letters

Volumn 13, Issue 2, 2017, Pages 800-804

  Tomizawa, Minoru ^a   Shinozaki, Fuminobu ^a   Motoyoshi, Yasufumi ^a   Sugiyama, Takao ^a   Yamamoto, Shigenori ^a   Ishige, Naoki ^a  

^a SHIMOSHIZU HOSPITAL   (Japan)

Author keywords

2 Deoxyglucose; Cyclin D1; HCC; Matrix metalloproteinase; Sorafenib

Indexed keywords

CYCLIN D1; DEOXYGLUCOSE; GELATINASE B; SORAFENIB;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG FIBROBLAST; PLC PRF 5 CELL LINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SCRATCH ASSAY;

EID: 85007355979     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.5510     Document Type: Article

References (22)

1. Cameron AM: Screening for viral hepatitis and hepatocellular cancer. Surg Clin North Am 95: 1013-1021, 2015.
2. Khan FZ, Perumpail RB, Wong RJ and Ahmed A: Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 7: 2155-2161, 2015.
3. Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL and Lee FT Jr: Liver ablation: Best practice. Radiol Clin North Am 53: 933-971, 2015.
4. Katano T, Mizoshita T, Senoo K, Sobue S, Takada H, Sakamoto T, Mochiduki H, Ozeki T, Kato A, Matsunami K, et al: The efficacy of transcatheter arterial embolization as the first-choice treatment after failure of endoscopic hemostasis and endoscopic treatment resistance factors. Dig Endosc 24: 364-369, 2012.
5. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99: 159-165,2008.
6. Kuczynski EA, Lee CR, Man S, Chen E and Kerbel RS: Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma. Cancer Res 75: 2510-2519, 2015.
7. Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett 367: 1-11, 2015.
8. Vaitheesvaran B, Xu J, Yee J, Q-Y L, Go VL, Xiao GG and Lee WN: The Warburg effect: A balance of flux analysis. Metabolomics 11: 787-796, 2015.
9. Jang M, Kim SS and Lee J: Cancer cell metabolism: Implications for therapeutic targets. Exp Mol Med 45: e45,2013.
10. Granja S, Pinheiro C, Reis RM, Martinho O and Baltazar F: Glucose addiction in cancer therapy: Advances and drawbacks. Curr Drug Metab 16: 221-242, 2015.
11. Zhang D, Li J, Wang F, Hu J, Wang S and Sun Y: 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett 355: 176-183, 2014.
12. Brito AF, Mendes M, Abrantes AM, Tralh�o JG and Botelho MF: Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: Focus on 2-deoxy-2-(18F)Fluoro-D-Glucose. Mol Diagn Ther 18: 495-504, 2014.
13. Davies B and Fried M: The L19 ribosomal protein gene (RPL19): Gene organization, chromosomal mapping, and novel promoter region. Genomics 25: 372-380, 1995.
14. Vandooren J, Van den Steen PE and Opdenakker G: Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev Biochem Mol Biol 48: 222-272, 2013.
15. Zhang Y, Shen Y, Cao B, Yan A and Ji H: Elevated expression levels of androgen receptors and matrix metalloproteinase-2 and -9 in 30 cases of hepatocellular carcinoma compared with adjacent tissues as predictors of cancer invasion and staging. Exp Ther Med 9: 905-908, 2015.
16. Wu J, Kou W, Gao MT, Zhou YN, Wang AQ, Xue QJ and Qiao L: Effects of {2-[(3-carboxy-1-oxoprogy1)amino]-2-deoxy-D-glucose} on human hepatocellular carcinoma cell line. Acta Pharmacol Sin 26: 635-640, 2005.
17. Tomizawa M, Kondo F and Kondo Y: Growth patterns and interstitial invasion of small hepatocellular carcinoma. Pathol Int 45: 352-358, 1995.
18. Takemura A, Che XF, Tabuchi T, Moriya S, Miyazawa K and Tomoda A: Enhancement of cytotoxic and pro-apoptotic effects of 2-aminophenoxazine-3-one on the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2, and the rat normal hepatocellular cell line RLN-10 in combination with 2-deoxy-D-glucose. Oncol Rep 27: 347-355, 2012.
19. Lv Y, Zhao S, Han J, Zheng L, Yang Z and Zhao L: Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer. Onco Targets Ther 8: 1941-1948, 2015.
20. Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M and Lampidis TJ: Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther 6: 732-741, 2007.
21. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, et al: A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71: 523-530, 2013.
22. Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T and Jain V: Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 181: 507-514, 2005.